Novo Nordisk's Wegovy Demonstrates Greater Weight Loss In Women With Heart Condition
Novo Nordisk's Wegovy Demonstrates Greater Weight Loss In Women With Heart Condition
Novo Nordisk's (NYSE:NVO) (OTC:NONOF) obesity medication, Wegovy, has been shown to cause more weight loss in women with prevalent heart disease than in men with the same condition.
諾和諾德（novonordisk）（OTC：NONOF）的肥胖症藥物Wegovy已被證明能夠在患有盛行心臟病的女性患者中比同樣情況的男性患者造成更多的體重減輕。
What Happened: In a recent analysis of study data, involving 1,145 patients, centered on a condition known as heart failure with preserved ejection fraction (HFpEF). The data from these studies was shared at the American Diabetes Association's scientific meeting in Orlando, Florida, Reuters reported on Monday.
最近對一項涉及1,145名患有心力衰竭伴有保留射血分數（HFpEF）狀況的患者的研究數據進行的分析顯示，Wegovy（化學名稱爲semaglutide）的這些研究數據在美國糖尿病協會於佛羅里達州奧蘭多舉辦的科學會議上被分享。路透社在星期一報道。
While the drug led to similar improvements in HFpEF symptoms in both genders, women lost an average of 9.6% of their weight, compared to men who lost about 7.2% of body weight. The trials were not designed to evaluate the treatment effects of Wegovy, chemically known as semaglutide, by biological sex.
雖然這種藥物對兩性都產生了類似的HFpEF症狀改善，但女性的體重平均減輕了9.6％，而男性的體重減輕了約7.2％。這些試驗並不是爲了評估Wegovy對生物性別的治療效果而設計的。
However, the greater weight loss in women did not result in significantly better improvements in heart failure symptoms. Further research is needed to identify the reasons for this discrepancy, the researchers said.
然而，女性的更多體重減輕並沒有導致心力衰竭症狀的顯着改善。研究人員表示，需要進一步研究以確定這種不一致的原因。
HFpEF accounts for about half of heart failure cases, mostly affecting overweight people and is especially common among women, prior studies have shown.
HFpEF佔心力衰竭病例的大約一半，主要影響超重人群，尤其是女性，先前的研究已經顯示出這種現象。
Why It Matters: Earlier in March, the Centers for Medicare and Medicaid Services (CMS) began reviewing the inclusion of Wegovy in its coverage for heart disease patients with obesity. This came after the FDA's action to expand the use of Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight.
今年三月，美國醫療保險和醫療補助服務中心（CMS）開始審查Wegovy是否應該納入其針對患有心臟病的肥胖病人的保險範圍。這是在FDA擴大Wegovy用於降低心血管疾病和肥胖或超重成人心血管死亡、心臟病發作和中風風險之後發生的。
In April, Germany's competition authority, Bundeskartellamt, cleared the planned acquisition of Cardior Pharmaceuticals GmbH by Novo Nordisk. Cardior is a biotech company focusing on heart diseases, specifically heart failure.
四月，德國競爭當局——聯邦卡特爾辦公室批准了諾和諾德計劃收購Cardior Pharmaceuticals GmbH。Cardior是一家專注於心髒疾病特別是心力衰竭的生物技術公司。
Goldman Sachs analysts re-rated Novo Nordisk, citing the potential for their weight-loss drugs. They expect the global sales of weight-loss drugs to reach $130 billion by 2030.
高盛分析師重新對諾和諾德進行了評級，認爲他們的減肥藥有潛力。他們預計全球減肥藥銷售額將在2030年達到1,300億美元。
Price Action: Novo Nordisk's stock in the NYSE closed at $141.96, with an after-hours price of $142.00. The 52-week high was $144.5, and the low was $75.56. The stock in OTC closed at $138.76.
Novo Nordisk在紐交所的股票收盤價爲141.96美元，盤後價格爲142.00美元。52周最高價爲144.5美元，最低價爲75.56美元。OTC的股票收盤價爲138.76美元。
Photo by Tobias Arhelger via Shutterstock
圖片由shutterstock提供
This story was generated using Benzinga Neuro and edited by Pooja Rajkumari
本報道使用Benzinga Neuro生成，並由Pooja Rajkumari編輯
譯文內容由第三人軟體翻譯。